2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144258
    PD-1/PD-L1-IN-14
    		Inhibitor 99.85%
    PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1.
    PD-1/PD-L1-IN-14
  • HY-153064
    MAX-10181
    		Inhibitor 98.07%
    MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor, with an IC50 value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases.
    MAX-10181
  • HY-120635
    BMS-1001 hydrochloride
    		Inhibitor 99.32%
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM.
    BMS-1001 hydrochloride
  • HY-P99941
    Retifanlimab
    Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA).
    Retifanlimab
  • HY-P10375
    BMS-986189
    		Inhibitor 98.16%
    BMS-986189 is a macrocyclic peptide inhibitor of PD-L1 (IC50: 1.03 nM), and can be used for cancer research.
    BMS-986189
  • HY-P99422
    Adebrelimab
    		Inhibitor
    Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).
    Adebrelimab
  • HY-P99108
    Penpulimab
    		Inhibitor 98.80%
    Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
    Penpulimab
  • HY-149213
    LSD1-IN-24
    		Inhibitor 99.20%
    LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research.
    LSD1-IN-24
  • HY-B1387
    Sulfamethoxypyridazine
    		Inhibitor 99.67%
    Sulfamethoxypyridazine is a long-acting sulfonamide antibiotic, for treatment of Dermatitis herpetiformis.
    Sulfamethoxypyridazine
  • HY-155101
    PD-L1-IN-3
    		99.52%
    PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research.
    PD-L1-IN-3
  • HY-P9972
    Spartalizumab
    		Inhibitor 99.50%
    Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC).
    Spartalizumab
  • HY-P99610
    Ezabenlimab
    		Inhibitor 99.82%
    Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo.
    Ezabenlimab
  • HY-P99114
    Sugemalimab
    		Inhibitor 98.3%
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
    Sugemalimab
  • HY-155959
    PD-1/PD-L1-IN-33
    		Inhibitor 99.57%
    PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity.
    PD-1/PD-L1-IN-33
  • HY-P990173
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
  • HY-P9996
    Reozalimab
    		Inhibitor 99.90%
    Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research.
    Reozalimab
  • HY-W771599
    ASC-69
    		Inhibitor 99.63%
    ASC-69 (APY69)is a potent and promising?PD-1/PD-L1 small-molecule inhibitor.
    ASC-69
  • HY-103048A
    PD-1/PD-L1-IN 3 TFA
    		Inhibitor 99.34%
    PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases.
    PD-1/PD-L1-IN 3 TFA
  • HY-P1812
    AUNP-12
    		Antagonist 99.31%
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
    AUNP-12
  • HY-145774
    PD-1/PD-L1-IN-23
    		Inhibitor 99.98%
    PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice.
    PD-1/PD-L1-IN-23
Cat. No. Product Name / Synonyms Application Reactivity